Vertex Prices Telaprevir At $49,200 For Course Of Therapy

In addition to setting a premium price over that for Merck's competing boceprevir, Vertex also indicated it still plans to go it alone on U.S. commercialization despite Merck/Roche alliance.

More from Archive

More from Pink Sheet